India DCGI Warning Seen Hurting Sales Of Avandia
This article was originally published in PharmAsia News
Executive Summary
At least three of India's generics makers can expect reduced sales of one of their drugs in the wake of a warning by their country's regulator about rosiglitazone. The drug is the API of GlaxoSmithKline's Avandia for keeping blood sugar levels low in diabetes patients. The GSK drug and generics made by India's Sun Pharmaceuticals, Dr. Reddy's Laboratories, Torrent Pharmaceuticals and 30 other companies contribute to sales to as many as 10 million of the nation's 41 million diabetics. The Drugs Controller General of India ordered the makers of the drug to include a warning of risks to diabetics who also have heart problems. The drug has a competitor, ploglitazone, already made by several other Indian drug makers, so physicians already have begun switching their patients. (Click here for more